128 related articles for article (PubMed ID: 27503930)
1. TPL2 Is an Oncogenic Driver in Keratocanthoma and Squamous Cell Carcinoma.
Lee JH; Lee JH; Lee SH; Do SI; Cho SD; Forslund O; Inn KS; Lee JS; Deng FM; Melamed J; Jung JU; Jeong JH
Cancer Res; 2016 Nov; 76(22):6712-6722. PubMed ID: 27503930
[TBL] [Abstract][Full Text] [Related]
2. Loss of Tpl2 activates compensatory signaling and resistance to EGFR/MET dual inhibition in v-RAS transduced keratinocytes.
Kelley MB; Geddes TJ; Ochiai M; Lampl NM; Kothmann WW; Fierstein SR; Kent V; DeCicco-Skinner K
PLoS One; 2022; 17(3):e0266017. PubMed ID: 35325006
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor 2 mRNA-binding protein-3 as a marker for distinguishing between cutaneous squamous cell carcinoma and keratoacanthoma.
Kanzaki A; Kudo M; Ansai S; Peng WX; Ishino K; Yamamoto T; Wada R; Fujii T; Teduka K; Kawahara K; Kawamoto Y; Kitamura T; Kawana S; Saeki H; Naito Z
Int J Oncol; 2016 Mar; 48(3):1007-15. PubMed ID: 26782292
[TBL] [Abstract][Full Text] [Related]
4. Trisomy 7 in keratoacanthoma and squamous cell carcinoma detected by fluorescence in-situ hybridization.
Cheville JC; Bromley C; Argenyi ZB
J Cutan Pathol; 1995 Dec; 22(6):546-50. PubMed ID: 8835173
[TBL] [Abstract][Full Text] [Related]
5. Survivin Modulates Squamous Cell Carcinoma-Derived Stem-Like Cell Proliferation, Viability and Tumor Formation in Vivo.
Lotti R; Palazzo E; Petrachi T; Dallaglio K; Saltari A; Truzzi F; Quadri M; Puviani M; Maiorana A; Marconi A; Pincelli C
Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26771605
[TBL] [Abstract][Full Text] [Related]
6. Immunoexpression of Bcl-x in squamous cell carcinoma and keratoacanthoma: differences in pattern and correlation with pathobiology.
Tan KB; Lee YS
Histopathology; 2009 Sep; 55(3):338-45. PubMed ID: 19723149
[TBL] [Abstract][Full Text] [Related]
7. EGFR and MYC gene copy number aberrations are more common in squamous cell carcinoma than keratoacanthoma: a FISH study.
Jacobs MS; Persons DL; Fraga GR
J Cutan Pathol; 2013 May; 40(5):447-54. PubMed ID: 23521519
[TBL] [Abstract][Full Text] [Related]
8. Keratoacanthoma and other types of squamous cell carcinoma with crateriform architecture: classification and identification.
Misago N; Inoue T; Koba S; Narisawa Y
J Dermatol; 2013 Jun; 40(6):443-52. PubMed ID: 23414327
[TBL] [Abstract][Full Text] [Related]
9. Histopathological diagnosis of epithelial crateriform tumors: Keratoacanthoma and other epithelial crateriform tumors.
Ogita A; Ansai SI; Misago N; Anan T; Fukumoto T; Saeki H
J Dermatol; 2016 Nov; 43(11):1321-1331. PubMed ID: 27076258
[TBL] [Abstract][Full Text] [Related]
10. p53 oncoprotein expression and proliferation index in keratoacanthoma and squamous cell carcinoma.
Kerschmann RL; McCalmont TH; LeBoit PE
Arch Dermatol; 1994 Feb; 130(2):181-6. PubMed ID: 8304756
[TBL] [Abstract][Full Text] [Related]
11. Differences in the mitochondrial microsatellite instability of Keratoacanthoma and cutaneous squamous cell carcinoma.
Alam MR; Alsulimani A; Haque S; Jung HR; Lee JH; Jeon CH; Kim DK
Cancer Genet; 2021 Aug; 256-257():115-121. PubMed ID: 34111657
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous Squamous Cell Carcinoma.
Parekh V; Seykora JT
Clin Lab Med; 2017 Sep; 37(3):503-525. PubMed ID: 28802498
[TBL] [Abstract][Full Text] [Related]
13. Keratoacanthoma: Update on the Debate.
Nirenberg A; Steinman H; Dixon A
Am J Dermatopathol; 2021 Apr; 43(4):305-307. PubMed ID: 33395044
[TBL] [Abstract][Full Text] [Related]
14. Distinguishing Keratoacanthoma from Well-Differentiated Cutaneous Squamous Cell Carcinoma Using Single-Cell Spatial Pathology.
Veenstra J; Ozog D; Loveless I; Adrianto I; Dimitrion P; Subedi K; Friedman BJ; Zhou L; Mi QS
J Invest Dermatol; 2023 Dec; 143(12):2397-2407.e8. PubMed ID: 37419445
[TBL] [Abstract][Full Text] [Related]
15. Natural course of keratoacanthoma and related lesions after partial biopsy: clinical analysis of 66 lesions.
Takai T; Misago N; Murata Y
J Dermatol; 2015 Apr; 42(4):353-62. PubMed ID: 25676096
[TBL] [Abstract][Full Text] [Related]
16. The Bcl-xL inhibitor of apoptosis is preferentially expressed in cutaneous squamous cell carcinoma compared with that in keratoacanthoma.
Vasiljević N; Andersson K; Bjelkenkrantz K; Kjellström C; Månsson H; Nilsson E; Landberg G; Dillner J; Forslund O
Int J Cancer; 2009 May; 124(10):2361-6. PubMed ID: 19165861
[TBL] [Abstract][Full Text] [Related]
17. DNA image cytometry of keratoacanthoma and squamous cell carcinoma.
Herzberg AJ; Kerns BJ; Pollack SV; Kinney RB
J Invest Dermatol; 1991 Sep; 97(3):495-500. PubMed ID: 1875048
[TBL] [Abstract][Full Text] [Related]
18. Subungual keratoacanthoma: analysis of cell proliferation and copy number variation of oncogenes compared with periungual squamous cell carcinoma.
Honma M; Kato N; Hashimoto M; Takahashi H; Ishida-Yamamoto A; Iizuka H
Clin Exp Dermatol; 2011 Jan; 36(1):57-62. PubMed ID: 20456385
[TBL] [Abstract][Full Text] [Related]
19. PKK deletion in basal keratinocytes promotes tumorigenesis after chemical carcinogenesis.
Chen L; Hayden MS; Gilmore ES; Alexander-Savino C; Oleksyn D; Gillespie K; Zhao J; Poligone B
Carcinogenesis; 2018 Mar; 39(3):418-428. PubMed ID: 29186361
[TBL] [Abstract][Full Text] [Related]
20. New perspectives on role of tumor microenvironment in progression of cutaneous squamous cell carcinoma.
Nissinen L; Farshchian M; Riihilä P; Kähäri VM
Cell Tissue Res; 2016 Sep; 365(3):691-702. PubMed ID: 27411692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
